Simvastatin and preparation of polyunsaturated phospholipids produce similar changes in the phospholipid composition of high-density lipoproteins during hypercholesterolemia.

Abstract	We studied the phospholipid composition of high-density lipoproteins in patients with coronary heart disease and hypercholesterolemia treated with simvastatin (Zocor, inhibitor of the key enzyme of cholesterol synthesis) and preparation of polyunsaturated phospholipids (lipostabil forte). Simvastatin produced a hypolipidemic effect and modulates the phospholipid composition of high-density lipoproteins (similarly to lipostabil forte). These changes contribute to functional activity of high-density lipoproteins in the reverse cholesterol transport.
Authors	I N Ozerova, N M Akhmedzhanov, N V Perova, I V Paramonova
Journal	Bulletin of experimental biology and medicine (Bull Exp Biol Med) Vol. 139 Issue 2 Pg. 210-2 (Feb 2005) ISSN: 0007-4888 [Print] United States
PMID	16027809 (Publication Type: Clinical Trial, Comparative Study, Journal Article, Randomized Controlled Trial)
Chemical References	Anticholesteremic Agents Lipoproteins, HDL Phosphatidylcholines Phospholipids lipostabil Simvastatin
Topics	Adult Aged Anticholesteremic Agents (therapeutic use) Coronary Disease (complications) Humans Hypercholesterolemia (blood, drug therapy, etiology) Lipoproteins, HDL (blood, chemistry) Middle Aged Phosphatidylcholines (therapeutic use) Phospholipids (analysis, blood) Simvastatin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!